임상1상 용량 증대 - 4번째 용량 시험
Sep 09, 2015EVENTSHit 978
The third cohort (100 mg) in dose escalation of Phase I clinical trial to evaluate the safety was finished successfully. The safety monitoring committee (SMC) recommended a dose escalation to the next level (140 mg). Three clinical sites in the USA started recruitment of patients with solid tumor for the forth cohort.
|Next||메드팩토, 3번째 글로벌 공동 임상… 프레드 허친슨과 운영 계약|